SCHEMBL7216346

SCHEMBL7216346

Cc1c2c(nn1C)-c1c(C(=O)Nc3ccn(C)n3)c[nH]c1CCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
GRM5 P41594 3/20 0.39
MAPK7 Q13164 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CCNC P24863 1/20 0.35
CDK8 P49336 1/20 0.35
CDK19 Q9BWU1 1/20 0.35
NOTUM Q6P988 1/20 0.34
SYK P43405 1/20 0.34
RPS6KA3 P51812 1/20 0.34
RPS6KA2 Q15349 1/20 0.34
PDE4B Q07343 1/20 0.33
PDE4D Q08499 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6833400 0.83 TRPV4 (0.35) NPC1RAB9AKDM4EALDH1A1LMNA
SCHEMBL7221974 0.81 GRM4 (0.43) NPC1RAB9AGRM5MAPK7KDM4E
SCHEMBL6835980 0.80 SPR (0.34) NOTUMKMT2A
SCHEMBL7216152 0.80 PDE4B (0.42) NPC1RAB9AGRM5MAPK7SYK
SCHEMBL6834410 0.75 NPC1 (0.36) NPC1RAB9AGRM5MAPK7KDM4E
SCHEMBL7218318 0.74 LMNA (0.36) NPC1RAB9AGRM5MAPK7KDM4E
SCHEMBL7222852 0.69 NPC1 (0.43) NPC1RAB9AGRM5KDM4EALDH1A1
SCHEMBL6834309 0.69 LMNA (0.42) NPC1RAB9AKDM4EALDH1A1LMNA
SCHEMBL6834487 0.68 GAA (0.43) NPC1RAB9AGRM5KDM4EALDH1A1
SCHEMBL7218324 0.68 MAPT (0.42) NPC1RAB9AKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6653471-B2 Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction NEUROGEN CORPORATION 2003-11-25 US disclosed